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The authors have retrospectively analyzed selected surgical and pathological observations made among a
group of 20 patients harboring recurrent cranial base meningiomas in an attempt to reveal which factors
may be important in predicting tumor recurrence. This cohort was compared with a group of 34 patients
with cranial base meningiomas that underwent primary resection and in whom tumor recurrence has not
been demonstrated over a median follow-up period of 33 months. Features analyzed included brain,
cranial nerve, carotid artery, or muscle invasion as well as tumor cellularity, nucleolar prominence,
cellular pleomorphism, and percentage of cells staining positive for the Ki-67 antigen. As expected,
increased cellularity and tumor necrosis were relatively more prevalent in recurrent tumors. With regard
to tumor type, atypical and anaplastic tumors were more common in the group of patients with recurrent
tumor compared with the primary group (p < 0.02). As expected, increased cellularity was relatively
more prominent in recurrent tumors. Invasion of muscle and bone (72%) was more frequently associated
with recurrent tumors, suggesting that these characteristics may be important features of recurrent skull
base meningiomas.
Key Words * skull base * meningioma * prognostic factor
The identification of predictors of recurrence of skull base meningiomas remains an important area of
study in neurosurgery. The subject becomes more relevant as operative techniques improve and expand
the number of tumors that are amenable to surgical resection.[2,12,13] Additionally, the increasing
availability of alternative therapies, such as radiosurgery, makes an objective assessment of the efficacy
of surgical resection more important.[10,17,24,26]
Skull base meningiomas account for 25 to 30% of all meningiomas, yet their rate of recurrence is
disproportionally high at 40 to 50%.[14] This compares to an overall meningioma rate of recurrence of
10 to 30%.[19] Although some of this high rate of recurrence may be attributed to the difficulty of
exposing and adequately removing these lesions, it is not clear if factors other than tumor location might
be identified that could characterize these lesions. The purpose of this study was to examine standard
clinical, surgical, and pathological parameters in patients with recurrent and nonrecurrent skull base
meningiomas treated at our institution to see if we could identify factors that might be associated with
tumor recurrence.
CLINICAL MATERIAL AND METHODS
Patient Selection
A total of 54 patients (40 women/14 men) with skull base meningiomas were studied retrospectively.
Each patient underwent surgery performed by a member of the faculty of the Department of
Neurosurgery at the University of Southern California University Hospital between August 1991 and
August 1994. This is a series of patients with skull base meningiomas with progressing clinical signs and
symptomatology in whom careful follow up was obtained. However, no attempt was made to match
these two groups of patients with regard to any variable. All the pathological slides were interpreted by a
single neuropathologist (D.R.H.). Thirty-four of these patients (27 women/seven men) had nonrecurrent,
or primary, meningiomas and the remaining 20 patients (13 women/seven men) had recurrent tumors.
The median age of the patients with nonrecurrent tumors was 54 years, and the median age of the
patients with recurrent tumors was 51 years.
Tumor Location
The tumor locations were broadly categorized as existing in one of the following sites and stratified by
nonrecurrence/recurrence: orbital region (9 patients), olfactory groove/subfrontal/planum sphenoidale (6
patients), parasellar (8 patients), cavernous sinus (12 patients), sphenoid wing (6 patients), and
petroclival/petrous apex (13 patients) (Table 1).
Clinical Signs and Symptoms
Several clinical signs and symptoms were evaluated in each patient. These included duration of
symptoms (in months), visual acuity/field defects, cranial nerve three, four, and six deficits, other cranial
nerve deficits, motor or sensory deficits, headaches, proptosis, and alterations in cognition. A clinical
sign or symptom was only reported for a given tumor if it represented a new finding in that patient.
Therefore, if a patient initially presented with visual acuity defects that did not improve following the
initial surgery, the defect would not be noted if the tumor recurred.
Surgical and Pathological Observations
A number of surgical observations were also tabulated. These included muscle or bone invasion, cranial
nerve invasion, cavernous sinus invasion, carotid artery encasement, and gross-total tumor resection.[7,8]
A gross-total resection was defined as a Simpson Grade I or II and a subtotal resection was defined as a
Simpson Grade III, IV, or V.[23] Muscle, bone, and cranial nerve invasion, if observed surgically, had to
be verified pathologically.
The tumors were classified according to the World Health Organization classification[5] (typical,
atypical, or anaplastic) for central nervous system tumor malignancy. These included the presence of
mitotic figures, increased cellularity, brain invasion, nuclear pleomorphism, tumor necrosis, and
nucleolar prominence.[5,11] The Ki-67 labeling index[3,22] using MIB-1 antibodies was analyzed in 27
of 34 primary tumors and 12 of 20 recurrent tumors. This value was determined by calculating the mean
labeling index for the five microscopic fields with the highest labeling indices.
Statistical Analysis
The Student's t-test was used to compare the data from the recurrent and nonrecurrent groups. A
probability value of less than 0.05 was considered significant.
RESULTS
Of the clinical signs and symptoms that were evaulated (Table 2), only the duration of symptoms was
noted to be statistically significant between the groups with primary and recurrent meningioma. In the
group with primary meningiomas, the average duration of symptoms was 38 months, whereas in the
group whose tumors recurred, the average duration of symptoms was 4.6 months (p < 0.05). Visual
acuity or visual field defects were present in 38% of patients with primary tumors and 50% of those with
recurrent tumors. Involvement of cranial nerves three, four, and six was more common in nonrecurrent
tumors (41%) versus recurrent tumors (25%). Proptosis was more common in those patients with
recurrent tumors (35%) versus those with primary tumors (21%). These differences, however, were not
statistically significant. In the remainder of the parameters tested (other cranial nerve deficits, motor or
sensory deficits, and headaches) there was little difference in the incidence between patients with
primary and those with recurrent tumors.
In the category of surgical observations (Table 3), muscle or bone invasion was noted to be significantly
more common in recurrent (72%) versus primary (38%) tumors (p < 0.02). Carotid artery encasement
was relatively more common in recurrent tumors (39%) versus nonrecurrent lesions (26%). For the
remainder of the parameters tested (cranial nerve invasion, cavernous sinus invasion, and incidence of
gross-total resection) there was virtually no difference between the primary and recurrent tumor
populations.
With regard to pathological observations (Table 4), the presence of mitotic figures was noted more
commonly in recurrent (44%) compared with nonrecurrent (22%) tumors (p < 0.05). Increased cellularity
was more common in recurrent lesions (28%) than in primary lesions (13%). The presence of brain
invasion was as common in recurrent as nonrecurrent lesions (5% vs. 3%). Similarly, the presence of
prominent nucleoli was noted more frequently in recurrent (33%) than in primary (19%) tumors. In
addition, atypical and anaplastic tumors were more prevalent in the recurrent group than in the primary
group (35% vs. 12%). There was virtually no difference in the incidence of nuclear pleomorphism or
tumor necrosis when comparing primary and recurrent tumor groups. Although the Ki-67 labeling index
was higher in the recurrent tumors (5% vs. 3.9%), this difference was not statistically significant.
DISCUSSION
Recurrent skull base meningiomas exhibit clinical, surgical, and pathological qualities that distinguish
them from nonrecurrent skull base meningiomas. Each of the three broad areas of examination in this
study: clinical signs and symptoms, surgical observations, and pathological observations, have been
studied in recent years.
With regard to this specific series of patients, it should be noted that this was a retrospective study, and
no attempt was made to match or stratify the primary and recurrent cohorts. Nevertheless, many of our
findings were consistent with those noted in previous studies of recurrent and aggressive
meningiomas.[28] For example, it was noted that a higher proportion of patients in the recurrent group
were male (35% vs. 21%); however, this observation did not reach statistical significance.
Clinical signs and symptoms play an important role in the diagnosis of recurrent tumors. Symptom
duration was found to be much shorter in patients with recurrent tumors (4.6 months) than in primary
tumors (38 months) (p < 0.05). This observation may be explained by the increased vigilance in
identifying relevant symptoms in patients who have undergone a previous tumor resection. However, it
may also be explained by the increased aggressiveness of recurrent tumors. Certain clinical signs and
symptoms, such as changes in visual acuity or the function of cranial nerves three, four, and six, were
thought to be more likely to be present in patients whose tumors were in specific locations such as the
cavernous sinus. Therefore, the presence of these clinical signs and symptoms was stratified with respect
to tumor location. As expected, patients with petroclival and petrous apex tumors do not commonly
present with changes in visual acuity (0% of tumors), but do commonly present with cranial nerve three,
four, and six symptoms (50% of tumors). Also as expected, patients with cavernous sinus tumors
frequently present with cranial nerve three, four, and six symptoms (71% of tumors). However, patients
with recurrent tumors in this location are unlikely to present with new cranial nerve three, four, and six
symptoms (20% of tumors) if these findings had not improved following the initial surgical resection.
These results are summarized in Table 5.
Surgical observations appear to play an important role in the prediction of skull base meningioma
recurrence. In our study, the intraoperative observation of muscle and bone invasion was noted more
frequently in recurrent tumors (72%) than in primary tumors (38%) (p < 0.05). This may be due to the
disruption of normal tissue planes or the inadvertent local seeding of tumor cells during the initial
surgery, leading to muscle and bone invasion upon recurrence. Alternatively, the increased invasiveness
of recurrent tumors may be caused by increased aggressiveness. As might be suspected, a subtotal
surgical resection is more likely to lead to a tumor recurrence than a gross-total resection.[5,21,28] As a
corollary, tumors in less accessible surgical sites, such as the skull base, were associated with a higher
rate of recurrence.[27] However, in this study, there was no difference in the observed rate of gross-total
resection between primary and recurrent tumors (21% vs. 22%).
Although there has been considerable investigation into the molecular biological behavior of
meningiomas in recent years, no single test or group of tests has emerged to predict the potential for
recurrence reliably. Traditionally, the Ki-67 labeling index has been cited as a predictor of tumor
aggressiveness and recurrence.[6,15,16] However, other studies have demonstrated that high Ki-67
values may be present in tumors that have benign histology and behavior.[4,20] In our study, the Ki-67
labeling index was 3.9% for primary tumors and 5% for recurrent tumors, a difference that did not reach
statistical significance, although not all specimens underwent Ki-67 analysis. However, an alternative
measure of tumor aggressiveness and potential for recurrence may be the tumor type. Seven of 20
recurrent tumors were atypical or anaplastic, versus only four of 34 primary tumors (p < 0.02). Although
cytogenetics were not evaluated in the current study, they have been previously investigated and
recurrent meningiomas have been found to have a high incidence of complex karyotypes such as
hypodiploidy and chromosomal structural rearrangements.[1,9,18,25]
The results of this study suggest that prognostic factors for skull base meningioma recurrence may be
unique in part due to their location and their propensity to invade muscle, bone, nerve, and the carotid
artery. Further study of mechanisms of tumor invasion into skull base structures is warranted to forestall
the incidence of recurrence in these locations.
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